Amgen Inc. (0R0T.L)
| Previous close | 247.13 |
| Open | 245.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 245.74 - 246.69 |
| 52-week range | 211.96 - 296.58 |
| Volume | |
| Avg. volume | 24,951 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 0.24 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Tuesday, May 14, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the genera
- PR Newswire
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.
- PR Newswire
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.
